Jan 8 (Reuters) - Kamada Ltd:
* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION
* KAMADA LTD - TOP-LINE RESULTS FROM PHASE 2 TRIAL OF ALPHA-1 ANTITRYPSIN ANTICIPATED IN H2 2019 Source text for Eikon: Further company coverage:
 